Article Details
Retrieved on: 2025-01-19 15:05:07
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Progression-free survival and objective response rate outcomes favored the tisotumab vedotin arm in the China subpopulation of the innovaTV 301 ...
Article found on: www.cancernetwork.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here